Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks IPOs and placings
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
GSK's Nucala gets fresh approval in China
(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older. The FTSE 100 pharmaceuticals giant said Nucala was the first anti-Interleukin-5 (IL-5) targeting treatment to receive approval for use in China for adult and adolescent patients with severe eosinophilic asthma.
It said asthma is a major public health concern in China, impacting an estimated 46 million adults, with about 6% of them suffering from severe asthma.
Severe asthma poses the most substantial challenges to daily life, increasing the risk of exacerbations requiring hospitalisation and potentially fatal asthma attacks.
In China, 15.5% of individuals with asthma have experienced an exacerbation necessitating hospitalisation in the preceding year.
The guidelines for bronchial asthma prevention and management, as per the 2020 edition from the asthma group of the Chinese Thoracic Society, underscored the unmet needs of Chinese patients with the condition and emphasised the potential benefits of targeted biologic therapy to reduce exacerbations, hospital visits, oral corticosteroid use, and improve asthma control and lung function.
GSK said the approval for the treatment of severe asthma with Nucala in China was grounded in positive data from a phase three trial specifically conducted among Chinese patients.
The results of the trial reinforced existing global data for mepolizumab's efficacy in patients with severe asthma, while the safety profile remained consistent with known information, with no new safety concerns identified among Chinese patients.
It said the approval was part of a comprehensive clinical development program,e that included four key clinical trials - DREAM, MENSA, SIRIUS, and MUSCA - which established the efficacy and safety of mepolizumab in patients with severe asthma displaying an eosinophilic phenotype.
The safety data was derived from pivotal, long-term, and real-world studies.
Notably, it was the second indication for mepolizumab in China, following its approval for use in adults with eosinophilic granulomatosis with polyangiitis (EGPA), who often have comorbid asthma, in 2021.
"We are delighted with this approval, supported by evidence in a Chinese population," said Kaivan Khavandi, GSK's senior vice president and global head of respiratory and immunology research and development.
"Millions of people in China with severe eosinophilic asthma can now potentially benefit from the advance in management that Nucala could offer - a testament to GSK's ongoing commitment to redefine respiratory disease management globally."
At 0834 GMT, shares in GSK were down 0.8% at 1,563.6p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity and Inclusion | Doing Business with Fidelity | Fidelity gender pay report | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Security | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.